Fiche publication
Date publication
mai 2016
Journal
Respirology (Carlton, Vic.)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BELTRAMO Guillaume
Tous les auteurs :
Borie R, Justet A, Beltramo G, Manali ED, Pradère P, Spagnolo P, Crestani B
Lien Pubmed
Résumé
Idiopathic pulmonary fibrosis (IPF) is a deadly disease with a median survival of approximately three years in historical cohorts. Despite increased knowledge of disease pathophysiology and selection of more targeted therapy, main clinical trials yielded negative results. However, two agents, pirfenidone and nintedanib, were recently shown to be effective in IPF and received marketing authorization worldwide. Both drugs significantly reduce functional decline and disease progression with an acceptable safety profile. Yet, none of these drugs actually improves or even stabilizes the disease or the symptoms perceived by the patient. Several other treatments and combinations are currently tested, and many more are ready for clinical trials. Their completion is critical for achieving the ultimate goal of curing patients with IPF.
Mots clés
cough, exacerbation, nintedanib, pirfenidone, pulmonary hypertension
Référence
Respirology. 2016 05;21(4):615-25
